Related Experiment Videos
[Pulmonary infection due to Mycobacterium malmoense]
W Handrick1, I Schwede, O Ebeling
1Institut für Medizinische Diagnostik, Berlin. Prof.W.Handrick@imd-Berlin.de
Pneumologie (Stuttgart, Germany)
|June 10, 2005
Summary
Mycobacterium malmoense, a rare cause of destructive pulmonary disease, proved difficult to eradicate in a patient despite multiple antibiotic therapies. Treatment challenges included patient compliance and side effects, highlighting the complexity of managing these infections.
Area of Science:
- Medical Microbiology
- Pulmonology
- Infectious Diseases
Background:
- Mycobacterium malmoense (M. malmoense) infections are rare, often occurring in patients with underlying pulmonary conditions.
- Pulmonary infections are the most common presentation of M. malmoense.
Observation:
- M. malmoense was successfully cultured from sputum of a 49-year-old patient diagnosed with destructive pulmonary disease.
- Initial treatment for presumed tuberculosis was modified to a multi-drug regimen including ethambutol, rifabutin, clarithromycin, and ciprofloxacin.
Findings:
- Despite prolonged therapy with azithromycin or clarithromycin, eradication of M. malmoense from the respiratory tract was unsuccessful.
- Treatment was complicated by insufficient patient compliance, therapy interruptions due to side effects, and excessive smoking.
Implications:
- This case underscores the challenges in treating M. malmoense pulmonary infections, particularly in patients with pre-existing lung disease and complicating factors.
- Optimal antibiotic strategies and management of patient adherence are crucial for improving outcomes in rare mycobacterial infections.